Author: Pichler-Stachl, Elisabeth ; Haas, Josef ; Joksch, Maike ; Pichler, Gerhard ; Mager, Corinna ; Schöll, Wolfgang ; Gold, Daniela ; Reif, Philipp ; Schmied, Christian ; Schneider, Verena ; Kirchhoff, Ebba

Abstract Introduction Preterm birth is defined as a live birth before 37 weeks of gestation and is associated with increased neonatal morbidity and mortality. The aim of this study is to compare the efficacy of hexoprenaline and atosiban for short- and long-term tocolysis and their effects on neonatal and maternal outcomes. Methods This retrospective cohort study included women with threatened preterm labor between 24 + 0 and 34 + 0 weeks of gestation without premature rupture of membranes. The tocolytic efficacy of hexoprenaline and atosiban was compared in women receiving one of the two medications for short- and long-term tocolysis. Continuous variables were compared using t-test or Mann–Whitney U test, as appropriate. Comparison of categorical variables between the two groups was done with χ2 test after Pearsonʼs and Fisherʼs exact test. Results 761 women were enrolled in this study; 387 women received atosiban and 374 women received hexoprenaline as their primary tocolytic agent. Atosiban showed a higher efficacy as a primary tocolytic agent (p = 0.000) within 48 hours. As regards long-term tocolysis, there were no differences between the treatment groups (p = 0.466). Maternal side effects such as tachycardia (p = 0.018) or palpitations (p = 0.000) occurred more frequently after the administration of hexoprenaline, while there were no differences between the two drugs administered with regard to any other maternal or neonatal outcome parameter. Conclusion Our retrospective study shows a significantly higher efficacy of atosiban in the first 48 hours, especially when administered at an early gestational age. There were no significant differences in terms of neonatal outcome but significantly more maternal adverse effects during the administration of hexoprenaline.

21 May 2021·Journal of AOAC INTERNATIONALQ4 · AGRICULTURAL & FORESTRY SCIENCE

Response Surface Methodology for Spectrophotometric Determination of Two β-Adrenergic Agonists-Terbium Chemosensors in Urine and Pharmaceutical Dosage Forms

Q4 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: El-Moghazy, Samir ; Al-Easa, Hala ; Fouad, Marwa ; Hanafi, Rasha ; Sakr, Marwa

AbstractBackgroundAccording to literature reports, none of the previous methods of analysis had touched the multivariate approach for the quantification of significant factors affecting the interaction of dobutamine or hexoprenaline with Terbium.ObjectiveTwo novel β-adrenergic agonists-lanthanide chemosensors were prepared for the determination of dobutamine and hexoprenaline in their pure and pharmaceutical dosage forms and in urine samples. Fabrication of the two chemosensors was based on their ligand-metal interaction with the lanthanide Terbium.MethodsA Plackett–Burman Design (PBD) was selected for the screening of four main variables (reaction time, metal volume, pH, and temperature). Applying Response Surface Methodology (RSM), a Central Composite Design (CCD) was executed for the optimization of the significant factors with narrower upper and lower limits. Spectrophotometric technique was exploited for the analysis of the two chemosensors.ResultsMaximum absorption was obtained at 299 and 298 nm for dobutamine-terbium and hexoprenaline-terbium complexes, respectively. Only factors that were found to bear significant effects on the formed complexes were promoted to the optimization level. Model verification was carried out, where target results coincided with those at the predicted levels, indicating the efficiency of the two proposed models. Validation of the proposed was implemented and linear ranges were found to be 3.30–13.50 and 1.90–10.00 µg/mL, for dobutamine and hexoprenaline, respectively.ConclusionsRecovery and relative standard deviation values by application in pure powder, pharmaceutical dosage forms and spiked urine samples indicated high accuracy and reproducibility. Wide-ranging linear values and comparatively low detection limits inferred the effectiveness of the proposed method.HighlightsRSM for optimization of spectrophotometric determination of dobutamine and hexoprenaline β-adrenergic agonists-lanthanide chemosensors; PBD was used for screening and CCD for optimization of variables affecting the spectrophotometric method; Determination of dobutamine and hexoprenaline in pure powder, pharmaceutical dosage form, and spiked urine samples was accomplished after method validation.

01 Sep 2018·Archives of Gynecology and ObstetricsQ4 · MEDICINE

Tocolysis with the β2-sympathomimetic fenoterol does not increase the occurrence of infantile hemangioma in preterm and term infants

Q4 · MEDICINE

Article

Author: Strowitzki, Thomas ; Pöschl, Johannes ; Bruckner, Thomas ; Wallwiener, Stephanie ; Fluhr, Herbert ; Freis, Alexander ; Kuon, Ruben-J ; Karmen, Christian ; Hudalla, Hannes ; Maul, Holger ; Michael, Zoe

PURPOSEβ₂-sympathomimetics are used in obstetrics as tocolytic agents, despite a remarkable profile of side effects. Recently, the β₂-sympathomimetic tocolytic drug hexoprenaline was identified as an independent risk factor for the development of infantile hemangioma (IH) in preterm infants. The aim of this study was to evaluate whether this observed effect was applicable to other β₂-mimetic tocolytic agents like fenoterol.METHODSClinical prospectively collected data of all infants born between 2001 and 2012 and admitted to the neonatal intensive care unit (NICU) at Heidelberg University Hospital and respective maternal data were merged. For the current retrospective cohort study, cases (IH) were matched to controls (no IH) at a ratio of 1:4, adjusting for birth weight, gestational age, gender and multiple gestations. Prenatal exposure to fenoterol and perinatal outcome were analyzed in the total cohort and in subgroups.RESULTSN = 5070 infants were admitted to our neonatal department, out of which n = 172 infants with IH were identified and compared to n = 596 matched controls. Exposure to fenoterol was not associated with a higher rate of IH in the total matched population (OR 0.926, 95% CI 0.619-1.384) or in a subgroup of neonates < 32 weeks of gestation or with a birth weight < 1500 g (OR 1.127, 95% CI 0.709-1.791). In the total matched population, prenatal exposure to glucocorticoids was associated with a reduced occurrence of IH (OR 0.566, 95% CI 0.332-0.964) and neonates with IH showed a prolonged total hospital stay compared to controls (69 vs. 57 days, p = 0.0033). Known risk factors for IH were confirmed by our large study cohort and included female gender, low birth weight, preterm birth and multiple gestations (all p < 0.005).CONCLUSIONSExposure to fenoterol during pregnancy does not increase the occurrence of IH. Further studies are needed to explore differences in the risk profiles of different β₂-sympathomimetic tocolytic drugs.

100 Deals associated with Hexoprenaline Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
D02396	Hexoprenaline Sulfate	R03AC06 R03CC05	DB08957

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Asthma	-	-	-
Pulmonary Disease, Chronic Obstructive	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis